The evolution of pharmacological treatment for Parkinson's disease

Recent Patents on CNS Drug Discovery

Volumn 3, Issue 1, 2008, Pages 50-54

  Almeida, Quincy J ^a   Hyson, H Christopher ^b  

^a WILFRID LAURIER UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Basal ganglia; Dopamine; Dopamine agonist; Medication; Monoamine oxidase inhibitor; Movement disorder; Parkinson's disease; Treatment

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CASPASE 3; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CREATINE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; GLUTAMATE RECEPTOR ANTAGONIST; INTERLEUKIN 1BETA CONVERTING ENZYME; ISTRADEFYLLINE; LEVODOPA; MINOCYCLINE; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; RILUZOLE; ROPINIROLE; ROTIGOTINE; SELEGILINE; UBIDECARENONE; UNINDEXED DRUG;

ADJUVANT THERAPY; ALCOHOLISM; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EATING DISORDER; ENZYME INHIBITION; FOOD; FOOD DRUG INTERACTION; HALLUCINATION; HUMAN; HYPERSEXUALITY; HYPOTENSION; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PALLIATIVE THERAPY; PARKINSON DISEASE; PATENT; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VALVULAR HEART DISEASE; VOMITING; WEIGHT GAIN;

ANIMALS; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; DRUG ADMINISTRATION ROUTES; HUMANS; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 38949160717     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488908783421500     Document Type: Review

References (63)

1. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004; 291(3): 358-64.
2. Muller T, Hefter H, Hueber R, et al. Is levodopa toxic? J Neurol 2004; 251 Suppl 6: VI/44-6.
3. Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinson's disease. CMAJ 2003; 168(3): 293-301.
4. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for parkinson's disease: an evidence-based review: report of the quality standards subcommittee of the American academy of neurology. Neurology 2002; 58(1): 11-17.
5. A second report on Levodopa. Med Lett Drugs Ther 1969; 11(18): 73-75.
6. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969; 21(4): 343-54.
7. Schwartz AM, Olanow CW, Spencer A. A double-blind controlled study of MK-486 in Parkinson's disease. Trans Am Neurol Assoc 1973; 98: 301-303.
8. Marsden CD, Parkes JD, Rees JE. A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet 1973; 2(7844): 1459-1462.
9. Lieberman AN, Derby BM, Feigenson J, et al. MK 486 and levodopa in treatment of Parkinsonism. Dis Nerv Syst 1973; 34(4): 167-71.
10. Gerlach M, Double R, Reichmann H, Riederer P. Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease. J Neural Transm Suppl 2003; (65): 167-83.
11. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351(24): 2498-508.
12. Fahn S. A new look at levodopa based on the ELLDOPA study. J Neural Transm Suppl 2006(70): 419-26.
13. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005; 252 Suppl 4: IV37-IV42.
14. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1(7954): 292-296.
15. Rao SS, Hofmann LA, Shakil A. Parkinson's disease: diagnosis and treatment. Am Fam Physician 2006; 74(12): 2046-2054.
16. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000; 123(11): 2297-305.
17. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16(3): 448-58.
18. Olanow CW, Obeso JA, Stocchi F. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol 2006; 2(7): 382-92.
19. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5(8): 677-87.
20. Modak, A.S., Kurogi, Y.: WO07004715 (2007).
21. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997; 37(1): 23-27.
22. Marion MH, Stocchi F, Quinn NP, Jenner P, Marsden CD. Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data. Clin Neuropharmacol 1986; 9(2): 165-81.
23. Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975; 25(12): 1144-1148.
24. Quinn N, Marsden CD, Parkes JD. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 1982; 2(8295): 412-5.
25. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64(2): 216-23.
26. Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 2007; 8(5): 657-64.
27. Johnston TH, Fox SH, Brotchie JM. Advances in the delivery of treatments for Parkinson's disease. Expert Opin Drug Deliv 2005; 2(6): 1059-73.
28. Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 2000; 55(11 Suppl 4): S72-77; discussion S78-81.
29. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problem with the current model. Ann Neurol 2000; 47(4 Suppl 1): S22-32; discussion S32-34.
30. Olanow CW, Obeso JA. Preventing levodopa-induced dyskinesias. Ann Neurol 2000; 47(4 Suppl 1): S167-76; discussion S176-178.
31. Hauser RA, Zesiewicz TA. Advances in the pharmacologic management of early Parkinson disease. Neurologist 2007; 13(3): 126-132.
32. Parkinson Study Group. Pramipexole vs Levodopa as initial treatment for parkinson disease: A Randomized Controlled Trial 10.1001/ jama.284.15.1931. JAMA 2000; 284(15): 1931-1938.
33. Noyes Y, Dick AW, Holloway RG. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life. Value Health 2006; 9(1): 28-38.
34. Ravenscroft P, Chalon S, Brotchie JM, Crossman AR. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Exp Neurol 2004, 185(1): 36-46.
35. Spengos K, Grips E, Karachalios G, Tsivgoulis G, Papadimitriou G. [Reversible pathological gambling under treatment with pramipexole]. Nervenarzt 2006; 77(8): 958-60.
36. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006; 21(4): 524-529.
37. Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005; 11(6): 381-386.
38. Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007; 64(5): 676-82.
39. Nomoto M, Nagai K Nakatsuka A, et al. Pharmacokinetic characteristics of agents applied in the treatment of Parkinson's disease. J Neurol 2006; 253 Suppl 3: iii53-iii59.
40. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995; 38(5): 771-777.
41. Pharmaceuticals BI. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Examine the Efficacy and Safety of Early Pramipexole Treatment Versus Delayed Pramipexole Treatment in Patients With New Onset Parkinson's Disease. In.
42. Guay DR. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother 2006; 4(4): 330-46.
43. Elmer L, Schwid S, Eberly S, et al. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci 2006; 248(1-2): 78-83.
44. Youdim MB, Bar Am O, Yogev-Falach M, et al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 2005; 79(1-2): 172-179.
45. Stocchi F. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. Int J Clin Pract 2006; 60(2): 215-21.
46. Sharma JC. Rasagiline - is there a place for this drug in managing Parkinson's disease? Int J Clin Pract 2006, 60(2): 132-133.
47. A randomizbd placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62(2): 241-248.
48. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61(4): 561-566.
49. Boireau A, Miquet JM, Dubedat P, Meunier M, Doble A. Riluzole and experimental parkinsonism: partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo. Neuroreport 1994; 5(16): 2157-2160.
50. Boireau A, Dubedat P, Bordier F, Peny C, Miquet JM, Durand G, et al. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. Neuroreport 1994; 5(18): 2657-2660.
51. Bameoud P, Mazadier M, Miquet JM, et al. Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat Neuroscience 1996; 74(4): 971-983.
52. Braz CA, Borges V, Ferraz HB. Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study. Clin Neuropharmacol 2004; 27(1): 25-29.
53. Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord 2002; 8(4): 271-276.
54. Rascol O, Olanow CW, Brooks DJ, Koch G, Truffinet P, Bejuit R. A 2-year, multicenter placebo-controlled; double blind, parallel-group study of the effect of riluzole on Parkinson's disease progression. Mov Disord 2002; 17(Supplement 5): P80; S39.
55. Bara-Jimenez W, Dimitrova TD, Sherzai A, Aksu K Chase TN. Glutamate release inhibition ineffective in levodopa-induced motor complications. Mov Disord 2006; 21(9): 1380-1383.
56. Hauser RA, Hubble JP, Truong DD, Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003; 61(3):297-303.
57. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002; 59(10): 1541-1550.
58. Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol 2004; 188(2): 491-494.
59. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007; 68(1): 20-280
60. Shults CW,, Haas R. Clinical trials of coenzyme Q10 in neurological disorders. Biofactors 2005; 25(14): 117-126.
61. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006; 66(5): 664-671.
62. Pattison LR, Kotter MR, Fraga D, Bonelli RM. Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease. J Neurol 2006; 253(9): 1137-1142.
63. Casarejos MJ, Menendez J, Solano RM, et al. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 2006; 97(4): 934-946.